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ttps://doi.org/10.1016/Background and purpose: The novel severe acute respiratory syndrome coronavirus 2
(SARS-Cov-2), now named coronavirus disease 2019 (COVID-19), may change the
risk of stroke through an enhanced systemic inflammatory response, hypercoagula-
ble state, and endothelial damage in the cerebrovascular system. Moreover, due to
the current pandemic, some countries have prioritized health resources towards
COVID-19 management, making it more challenging to appropriately care for other
potentially disabling and fatal diseases such as stroke. The aim of this study is to
identify and describe changes in stroke epidemiological trends before, during, and
after the COVID-19 pandemic. Methods: This is an international, multicenter, hospi-
tal-based study on stroke incidence and outcomes during the COVID-19 pandemic.
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al Care, Eskisehir Osmangazi University, Eskişehir, Turkey; kStroke Prevention and Atherosclerosis Research Centre, Robarts
University, London, Ontario, Canada; #Department of Clinical Neurological Sciences, Western University, London, Ontario, Can-
miology and Biostatistics, Schulich School of Medicine and Dentistry, Western University, London, Ontario, Canada; ††Depart-
of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran; ‡‡Chief of Cardiology, INECO Neurociencias, Rosario,
f Neurology, Carl Gustav Carus University Hospital, Technische Universit€at Dresden, Dresden, Germany; {{Department of Med-
nd Health Sciences, Universiti Putra Malaysia, Serdang, Malaysia; kkUniversity of Tennessee, Comprehensive Stroke center, Mem-
ndazione Istituto Neurologico 'Carlo Besta', Milan, Italy; ***Department of Neurology, Loyola University Health System, Stritch
o, USA; †††Clinical Neurology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran; ‡‡‡Department of Neurology,
nnesota, USA; §§§Department of Medicine and Neurology, Melbourne Brain Centre at The Royal Melbourne Hospital, University
stralia; {{{Neurology Department, Texas Tech Health University, El Paso, Texas, USA; kkkNational Neuroscience Institute, Sin-
ampus, Singapore; ###Department of Neurology and Stroke Unit, San Camillo de’ Lellis General District Hospital, Rieti, Italy;
euro-epidemiology Unit, SMDN-Centre for Cardiovascular Medicine and Cerebrovascular Disease Prevention, Sulmona,
ment of Neurology, School of Medicine, University of New Mexico, Albuquerque, New Mexico, USA; ‡‡‡‡Department of Neurol-
, Saint Louis University, USA; §§§§Departments of Neurology and Neurosurgery, Icahn School of Medicine at Mount Sinai, New
nt of Neurology, School of Medicine, Zanjan University of Medical Sciences, Zanjan, Iran; kkkkDepartment of Stroke and Cerebro-
University, Japan; ####Department of Neurology, Inje University, Ilsan Paik Hospital, Goyang, Republic of Korea; *****Graduate
l Science, China Medical University, Taipei, Taichung; †††††Department of Neurology, Mayo Clinic, Jacksonville, Florida, USA;
ovascular Medicine, National Cerebral and Cardiovascular Center, Suita, Osaka, Japan; {{{{{Department of Medicine and Insti-
gement and Evaluation, University of Toronto, Toronto, Canada; kkkkkInstitute for Clinical Evaluative Sciences, Toronto, Canada;
e, Faculty of Medicine and Health Sciences, Universiti Putra Malaysia, Serdang, Selangor, Malaysia; ******Department of Neurol-
utuaTerrassa, Terrassa (Barcelona), Spain; ††††††Department of Life Sciences, CBS, Manchester Metropolitan University, Man-
ent of Neurology, Geffen School of Medicine, UCLA, USA; §§§§§§Beijing Tiantan Hospital, Capital Medical University, China
Center for Neurological Diseases, Beijing, China; {{{{{{Department of Neurology, Monash Health and Department of Medicine,
Monash University, Australia; *******Department of Neurosciences, UCSD, USA; †††††††Neurologic Institute, Cleveland Clinic
linical Research Development Unit, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran; §§§§§§§Siriraj
of Medicine, Siriraj Hospital, Mahidol University, Bangkok, Thailand; {{{{{{{Department of Neurosurgery, Mount Sinai Hospi-
{{{{{Department of Neurology, Christian Medical College, Ludhiana, India; kkkkkkkDepartment of Biomedical and Clinical Sci-
sity of Milan, Milan, Italy; #######Department of Neurology, SUNY Downstate Medical Center, Brooklyn, New York, USA;
or Clinical Neurosciences, Salford Royal National Health Service Foundation Trust, Manchester Academic Health Science Centre,
lich School of Medicine and Dentistry, Western University, London, Ontario Canada; ‡‡‡‡‡‡‡‡David Geffen School of Medicine,
ter, Department of Neurology, University of California, Los Angeles, USA; §§§§§§§§Department of Neurology, Mashhad Univer-
ashhad, Iran; {{{{{{{{Department of Medicine, University of Alberta, Edmonton, Alberta, Canada; kkkkkkkkDepartment of
assachusetts Medical School, Worcester, Massachusetts, USA; ########Division of Cardiovascular Sciences, Lydia Becker Institute
mation, University of Manchester, UK; *********Manchester Centre for Clinical Neurosciences, Manchester Academic Health Sci-
NHS Foundation Trust, Salford, UK; †††††††††Department of Epidemiology and Biostatistics, Schulich School of Medicine and
ity, London, Ontario, Canada; ‡‡‡‡‡‡‡‡‡Department of Family Medicine, Schulich School of Medicine and Dentistry, Western
ario, Canada; §§§§§§§§§Department of Population Health, Luxembourg Institute of Health, Strassen, Luxembourg;
e Stroke Care Program, Sree Chitra Tirunal Institute for Medical Sciences and Technology (SCTIMST), Trivandrum 695 011, Ker-
d Department of Neurology, Attikon University Hospital, National & Kapodistrian University of Athens, Athens, Greece;
y, Karachi, Pakistan; **********Department of Medicine and Neurology, Melbourne Brain Centre at The Royal Melbourne Hospital,
Population Health and Immunity Division, The Walter and Eliza Hall Institute of Medical Research, Parkville, Australia;
eurology, National Cerebral and Cardiovascular Center, Suita, Osaka, Japan; ‡‡‡‡‡‡‡‡‡‡Neurology department of Iran Univer-
hran, Iran; and §§§§§§§§§§Neurology Department, Neuroscience Institute, Geisinger Health System, Danville, Pennsylvania, USA.
evision received May 1, 2020; accepted May 2, 2020.
to M. Reza Azarpazhooh, MD, Stroke Prevention and Atherosclerosis Research Centre, Robarts Research Institute, Western Uni-
anada. and Address correspondence to Mario Di Napoli, MD, Department of Neurology and Stroke Unit, San Camillo de Lellis




EFFECT OF COVID-19 PANDEMIC ON INCIDENCE OF CEREBROVASCULAR DISEASE 3stroke severity, subtype (ischemic/hemorrhagic), and outcomes (including in-hos-
pital mortality) in 2020 during COVID-19 pandemic, comparing them with the cor-
responding data from 2018 and 2019, and subsequently 2021. We will also use an
interrupted time series (ITS) analysis to assess the change in stroke hospitalization
rates before, during, and after COVID-19, in each participating center.
Conclusion: The proposed study will potentially enable us to better understand the
changes in stroke care protocols, differential hospitalization rate, and severity of
stroke, as it pertains to the COVID-19 pandemic. Ultimately, this will help guide
clinical-based policies surrounding COVID-19 and other similar global pandemics
to ensure that management of cerebrovascular comorbidity is appropriately priori-
tized during the global crisis. It will also guide public health guidelines for at-risk
populations to reduce risks of complications from such comorbidities.
Key Words: SARS-CoV-2—COVID-19—Pandemic—Stroke—Incidence—Mortality—
National crisis—Health policy
© 2020 Elsevier Inc. All rights reserved.Introduction
An emergence of pneumonia cases in Wuhan, Hubei
Province, China, was first reported to the World Health
Organization (WHO) on December 31, 2019.1 A novel
coronavirus, named severe acute respiratory syndrome
coronavirus 2 (SARS-Cov-2), which had not been previ-
ously identified in humans, was subsequently isolated
from these patients, and was identified as the source of
the acute respiratory illnesses, now named coronavirus
disease 2019 (COVID-19). On March 11, 2020, COVID-19
was subsequently declared a global pandemic by the
World Health Organization (WHO) and has spread to
over 212 countries/territories worldwide so far.2,3 This
has surpassed the spread of other viral respiratory tract
diseases such as severe acute respiratory syndrome
(SARS).4,5 Specifically, as of April 30th, 2020, there are
3,090,445 reported laboratory-confirmed cases world-
wide3, and this number is expected to continue increasing.
This has resulted in an unprecedented international public
health crisis that has prompted numerous countries to
implement nation-wide lockdowns to mitigate the spread
of the virus and reduce the burden on healthcare systems.
The public health burden of COVID-19 has reached
beyond that of any other infectious respiratory illness, as
it may have associations with non-communicable diseases
(NCDs), including cerebrovascular or cardiovascular dis-
orders (CVDs). Patients with COVID-19 often have vascu-
lar risk factors and comorbidities,6,7 which may increase
the need for hospitalization, and need for intensive care
unit admissions and/or intubation. It may also induce
vascular injury that would promote the risk of stroke.811
While prevention and management of COVID-19 is a
top global health priority, this should not come at the cost
of compromising the treatment and management of other
potentially life-threatening diseases.12 The present multi-
center, international study has been designed to assess
changes in stroke rates, severity, subtypes (ischemic/hem-
orrhagic), and outcomes before, during, and after theCOVID-19 pandemic. The results of this initiative can be
used as a monitoring model for public health authorities
and policymakers regarding the system's capacity during
a global crisis of this magnitude. Ultimately, enhanced
simultaneous surveillance of NCD and COVID-19 comor-
bidity in populations would generate the empirical data
needed to better understand the dual-disease burden and
to target coordinated care.
Study design
The CASCADE Study (Call to Action: SARS-Cov-2 and
Cerebrovascular DisordEr) is a retrospective and prospec-
tive international multicenter cohort study comparing the
rate, severity and outcomes of stroke before, during, and
following the COVID-19 outbreak.
The study aims to create a multicenter stroke registry
to: (1) describe changes in stroke clinical care approach
(including imaging, stroke-unit care admission, thrombol-
ysis, thrombectomy, neurosurgery availability, and out-
patient assistance in different countries during the
COVID-19 outbreak); (2) evaluate the incidence of CVD in
COVID-19 positive patients, as well as identifying clinical
markers predictive of CVD occurrence in COVID-19 posi-
tive patients; (3) identify the clinical, neuroimaging and
prognostic factors of CVD during the pandemic in com-
parison to the same period in 2018 and 2019, and subse-
quently, 2021.
Study population and data collection
CASCADE is a new initiative, and we foresee continu-
ous collaboration across multiple participating centers
worldwide (Fig. 1). Neurological and stroke centers, eval-
uating cerebrovascular disease patients (aged > 18) dur-
ing the COVID-19 pandemic will be included in the
project. For each participating center, the overall types of
acute phase stroke therapy utilized, the crude and age-
standardized stroke rate, vascular risk factors, stroke
severity, and stroke outcomes such as in-hospital
Fig. 1. World map depicting participating centers (white push pins) and their total COVID-19 cases, and total cases in the top 10 afflicted countries. Geographic
distribution of the cumulative number of reported COVID-19 cases per 1 million population is illustrated in a color-gradient. Data on COVID-19 cases are
updated as of April 30, 2020 (countries with more than 100 cases per one million of their population are highlighted).
4 S. ABOOTALEBI ET AL.mortality will be tracked and compared with the previous
corresponding months in 2018 and 2019, and in 2021 or
2022 if the disease progresses through 2021.
Other important data include the date of the first report
of COVID-19, the date of the latest quarantine, the date of
the end of quarantine, the date and nature of phased
social distancing and lock-down restrictions, and the date
and nature of relaxation of social distancing and lock-
down measures (if available) in each corresponding coun-
try/region, according to official local and governmental
reports. We will also obtain data regarding COVID-19
from international databases; e.g. the European Centre for
Disease Prevention and Control (ECDC),13 and the United
Nations Educational, Scientific and Cultural Organization
(UNESCO)-COVID-19 Educational Disruption and
Response.14 Environmental data, specifically, national air
quality, will be obtained through NASA's Giovanni OMI
visualization tool.15 We have developed a set of common
variables with their definitions to facilitate standardiza-
tion of data-collection among participating centers (Sup-
plement Table 1). The final database will include data
regarding important variables, such as stroke incidence,
stroke severity, vascular risk factors, medications, and
outcome (e.g. in-hospital mortality and disability).
Stroke will be defined according to the Stroke Council
of the American Heart Association/American Stroke
Association census definition.16 The severity of stroke will
be measured according to the National Institutes of
Health Stroke Scale (NIHSS). Stroke disability will be
assessed using the modified Rankin Scale (mRS) on
admission, at discharge, and longitudinally (30 days and
3 months follow-ups), if available. Depending on theparticipating centers' registry, we will include all
stroke (first-ever-stroke and recurrence) cases, stroke
subtypes such as acute ischemic stroke (AIS), intracere-
bral hemorrhage (ICH), cerebral venous thrombosis,
and subarachnoid hemorrhage (SAH). In addition, if
available, we will monitor prospectively cases admit-
ted with COVID-19 who develop strokes in hospital or
within two weeks after their discharge. We will also
identify stroke patients with a laboratory-confirmed
COVID-19 diagnosis.17 Further, given the limited avail-
ability of COVID-19 laboratory testing in some centers,
we will gather data regarding those clinically sus-
pected of having COVID-19 following a stroke. With
this approach, we can provide a broader understand-
ing of the larger incidence of both the communicable
and non-communicable related disease.Ethical considerations
Local Ethics Committee approval will be obtained
for each participating center. Data sharing will be
according to the institutional Ethics Committee’s poli-
cies and official agreements. We will use anonymized
data, secured in protected servers. The confidential
data will be saved in an encrypted and secured dataset
(e.g., RedCap, http://projectredcap.org/, Vanderbilt
University). Anonymized data obtained by each center
will be pooled together to be analyzed by the desig-
nated data processing center. A subject ID coding will
be designed to have a specific designation code for
each participating center that is only shared with the
data processing center and the corresponding site.
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Crude and standardized hospitalization rates of stroke
per month will be calculated using a direct method. We
will use a Poisson regression model with a log link to
compare the number of stroke hospitalizations during the
COVID-19 pandemic, as compared to corresponding
months in the previous and, possibly, upcoming years.
We will calculate risk ratios [with 95% confidence inter-
vals (CIs)] of the number of stroke hospitalizations within
the pandemic period, as compared to the periods before
and after COVID-19. We will use Kaplan-Meier survival
method within the study period and Cox-regression
model to estimate the hazard ratio (HR) with 95% CI of
in-hospital mortality. An interrupted time series (ITS)
analysis will be used to assess the change in stroke hospi-
talization rates after COVID-19 in each center. We will
compare the proportion of different stroke care manage-
ments (e.g. outpatient assistance, craniectomy utilization,
discharge setting, supported discharge) between the
COVID-19 pandemic and previous periods. These varia-
bles will be added as a time-varying confounder in the
ITS regression model. Prevalence of stroke subtypes and
important neuroimaging features (e.g. cortical vs. subcor-
tical, anterior vs. posterior circulation, stroke size and
location, etc.) will be estimated in proportion to total
admitted strokes. These variables will also be analyzed in
the ITS model as a time-varying confounder. Using an
autoregressive integrated moving average (ARIMA)
model (according to the Box-Jenkins-Tiao strategy), serial
autocorrelations of the hospitalization rates will be
assessed. The Q-statistic will test analytically whether the
autocorrelation function is different from a white noise
process. A lag plot will be created using the sample auto-
correlation coefficients, plotted against the corresponding
lags. We will calculate the Durbin-Watson (DW) statistic
to test the autocorrelation of the errors in the segmented
regression models.
Discussion
CASCADE is a new multicenter initiative to assess the
impact of the COVID-19 pandemic on stroke occurrence,
severity, care, and outcomes. The results of this initiative
will have multiple clinical and public health implications.
Similar to other major global crises (e.g. WWII), critical
periods of time surrounding COVID-19 can be catego-
rized as periods before, during, and after the pandemic.
Since the 1918 flu pandemic,18 the world has not experi-
enced a pandemic of this magnitude. Therefore, the pool-
ing of epidemiological, clinical, and laboratory data on
the COVID-19 pandemic is imperative to the success of
national and global public health initiatives directed
towards this novel virus, and future national and interna-
tional health crises. In addition to the COVID-19 viral epi-
demiology, a successful model should also include other
major diseases, including NCDs, identifying the risk forvulnerable populations (i.e. those with prior comorbid-
ities), and prioritizing preventive measures through
strengthening public protections and improving access to
health services. Combining these preventive measures for
COVID-19 with measures surrounding life-threatening
NCD, as well as focusing on screening and treatment pro-
grams during and after the pandemic is of major impor-
tance, and one of the priorities of the CASCADE study.
COVID-19 can affect stroke rate and outcomes
through various direct and indirect pathways. Among
20,812 patients confirmed to have COVID-19 in China
as of February 11, 2020, 2683 patients (12.8%) had
hypertension, and 873 (4.2%) had cardiovascular dis-
ease.6 Similarly, in Italy, in a subset of 355 patients who
died of COVID-19, 352 were found to have comorbid-
ities, including diabetes in 35.5%, ischemic heart disease
in 30%, atrial fibrillation in 24.5%, and stroke in 9.6% of
patients,7 The systemic inflammatory response from
SARS-Cov-2 may trigger the rupture or erosion of ath-
erosclerotic plaque,8,11 destabilize previous stroke or
coronary artery disease,9 and may be associated with
acute cardiac injury such as myocarditis.8,10
SARS-Cov-2 may also have a peripheral vascular detri-
mental effect due to its ability to act on Angiotensin-Con-
verting Enzyme 2 (ACE2) receptors, which play a major
role in regulating cardiovascular function.11,19 Further-
more, it also has a potential negative neurotropic effect
due to the expression of ACE2 receptors on neurons and
cerebral endothelial cells. This facilitates the rupture of
the blood-brain barrier and cerebral arteries,20 which sug-
gests the development of more severe and devastating
strokes21 in the presence of COVID-19. Finally, stroke-
induced suppression of the innate and adaptive immune
system is well described22 and may impact susceptibility
to, and severity of, SARS-Cov-2 infection in the acute
phase of stroke, ultimately impacting clinical outcomes.
Given that COVID-19 is closely related to SARS,23 we
anticipate similarities in cardiovascular presentations,
such as arrhythmias. Specifically, in a cohort study
(n=121), tachycardia (71.9%) and bradycardia (14.9%)
were reported in patients with SARS.24 In addition, hyp-
oxemia resulting from severe respiratory illness in
COVID-19, particularly in those with underlying CVDs
such as stroke and heart failure, may also lead to atrial
fibrillation7 and increased mortality rate.25 Finally,
COVID-19 has been associated with abnormalities in the
coagulation cascade.26
Similar to many other global health crises, COVID-19
may also indirectly affect the rate and severity of CVDs.
Prioritization of medical resources towards COVID-19
precautions and assistance, as seen in many countries,
may result in a reduction of resources for other potentially
fatal diseases.27 This is important as a healthcare system
collapse under significant burden from COVID-19 may,
directly and indirectly, affect all other major health condi-
tions (e.g., stroke), resulting in higher mortality and
6 S. ABOOTALEBI ET AL.morbidity among both infected and non-infected patients.
It is necessary to note that most countries heavily
impacted by COVID-19 are those that are typically more
impacted by the presence of concurrent NCD’s, rather
than communicable diseases in general (paper in prepara-
tion). As such, it is possible that the lack of prior exposure
to a pandemic of this magnitude could have resulted in a
lack of preparedness in terms of preventive and emer-
gency management plans.
COVID-19 may also indirectly affect CVDs through
heightened emotional responses, such as stress.28 Specifi-
cally, within the 3 weeks following the 2011 Great East
Japan Earthquake and Tsunami disaster, there was a sig-
nificant increase in the number of cardiovascular events,
including acute coronary syndrome or congestive heart
failure, without any change in the rate of stroke.29 A study
observed a French population over 4 Football World Cup
events, a time period that is considered stressful for the
audience viewing the matches.30 Interestingly, the study
found a decrease in the rate of stroke, potentially due to a
state of the euphoria associated with viewing the football
game.30 A similar study in Germany during the 2006
World Cup found that the incidence of cardiac emergen-
cies increased significantly on days that the German team
was playing.31 The difference in the incidence of CVDs
during these national disasters and events may be
explained by the heterogeneous nature of CVD occur-
rences.29 Further, due to the implementation of mitigation
strategies that have resulted in physical isolation of large
subsets of the population, COVID-19 has indirectly, and
beneficially, impacted air quality and pollution. Recent
observational satellite images obtained from NASA
depicted improvements in air quality over China during
periods of quarantine in February 2020, a time which had
seen nation-wide business closures and prohibited vehic-
ular transportation. Specifically, up to 30% reductions in
NO2 emissions, and up to 40% reductions in CO2 emis-
sions have been observed.32,33 While similar reductions
are normally seen during Chinese Lunar New Year due to
business closures, the emissions typically increase once
again in the following weeks.34 However, due to the quar-
antine, the number of festivities and outdoor events have
been reduced. Similar trends have been observed in states
that have implemented “shelter-in-place” orders within
the United States.35 As of March 9, 2020, Italy, which
had also implemented a nation-wide lockdown, has
also seen improvements in air quality. Specifically,
from March 14 until March 25, 2020, Rome had seen
up to a 35% decrease in NO2 as compared to the same
period in 2019.36 This is particularly important as air
quality has been shown to have effects on stroke and
other NCD's.37 Conversely, it is possible that pro-
longed homestay due to the quarantine may lead to
increased sedentary behaviors, physical inactivity, and
unhealthy dietary intake habits, leading to increasing
or worsening chronic health conditions.38The CASCADE study is feasible and can provide scien-
tific answers for many of the aforementioned hypotheses.
The data will be gathered in a challenging, resource-lim-
ited situation during the COVID-19 pandemic, which is
having an enormous impact on healthcare and the econ-
omy in many countries. The proposed initiative can pro-
vide a wide range of information, from individual-based
health related issues to changes in health policy in high,
middle, and low-income countries. As well, the CAS-
CADE registry can also be combined with other interna-
tional stroke registries to expand the knowledge in this
field. In addition, our data will reflect the real-world and
systemic healthcare challenges currently facing many cen-
ters around the world. Data will be gathered based on
available stroke information at each center. It is possible
that those with transient ischemic attacks (TIAs) and
minor strokes may not present to Emergency Rooms due
to fear of contracting COVID-19 from the hospital, and/
or social distancing measures. However, we would ulti-
mately not expect to see a significant decrease in the rate
of severe and fatal stroke presentations. Therefore, any
changes in the rate, severity, and outcome of stroke within
the study period will likely reflect the direct and indirect
consequences of COVID-19.Conclusion
The worldwide convergence of NCD and communica-
ble infectious diseases has the potential to overstretch
global health systems. The CASCADE initiative can
potentially shed light on challenges related to stroke care
as a major NCD within this context. Identifying and ana-
lyzing the current health-related data during the COVID-
19 period will help to optimize resource allocation, con-
duct proper assessments to objectively identify the nature
of the problem, implement strategies to address the issue
in the most effective and efficient way, and better prepare
for future viral outbreaks.Acknowledgment
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